ELDN Eledon Pharmaceuticals Inc

$ELDN Piotr Witkowski, M.D., Ph.D. (University of Chicago) presented on the Breakthrough T1D-funded clinical trial for tegoprubart, an alternative to standard immunosuppressants, developed by T1D Fund company Eledon. Tegoprubart is maintaining its success: all 12 participants who have received an islet cell transplant are off external insulin (7 after one transplant; 5 after two) with stable blood-sugar levels, no side effects, and no toxicity in the kidneys. An upcoming clinical trial will test tegoprubart in people with T1D and chronic kidney disease (CKD)—the first time this population is eligible for an islet cell therapy.

$ELDN The man, myth, legend Dr. Witkowski at Breakthrough T1D’s conference in Philly providing positive updates on Eledon’s trials!

$ELDN Eledon could structure a $500.X million secured bond issuance, leveraging authorized equity as contingent collateral, subject to lender acceptance and collateral coverage requirements. Proceeds would finance Phase 3 trials and extend cash runway without immediate dilution. Debt repayment could occur through strategic M&A, refinancing, or licensing proceeds, mitigating near-term equity dilution.

$ELDN 🏥 Eledon Pharmaceuticals, Inc. presented new Phase 2 BESTOW data showing tegoprubart-treated kidney transplant patients had statistically significant improvements in quality-of-life and symptom burden versus tacrolimus through 12 months. Market-relevant event

$ELDN The comment period is happening now for the islet act! This was posted by the one and only Dr. Camillo Ricordi. All the big players are helping to get this passed

$ELDN 🏥 Eledon Pharmaceuticals, Inc.'s investigational immunosuppression therapy tegoprubart is being tested in a newly launched Breakthrough T1D-funded clinical trial of islet cell transplantation in people with type 1 diabetes and chronic kidney disease, with the first participant transplanted. Prioritized by relevance

$ELDN I'm expecting a big run after kidney week... Eledon ppt is this Friday... The title is solid... Specific comparison between tacro vs. tego... This is going to get very interesting!!! Massive ♉

$ELDN took long enough to get here, we're at support. This is a good spot to add IMO. Let's go!

$ELDN PHASE 3 FINANCING STRATEGY — WITHOUT IMMEDIATE DILUTION Eledon could potentially raise $150 million through secured corporate bonds to finance its Phase 3 LEGACY trial without immediately diluting existing shareholders. The additional authorized shares could potentially support a negotiated contingent security arrangement, although authorized shares alone are not collateral. Bondholders would receive interest, hypothetically around 10% annually, with principal repayment potentially coming from a future pharmaceutical acquisition. KEY ADVANTAGES • No immediate shareholder dilution. • Funding to advance Phase 3. • Preserves existing shareholders’ upside if the company succeeds. • Potential repayment through acquisition proceeds.

$ELDN That brings my average cost under 3.00. I just stopped posting because there was nothing to say. Until this recent spike the price has just been falling due to people bailing and market makers just makes the shares dance around like their puppets. Making them rich as we all watch our investment dry up until the capitulation /correction have been exhausted. This could be the rebound that will be the catalyst for bullish momentum.

$ELDN seeing the continued sell pressure I'd say an ATM agent has been likely selling since July. Next quarterly reporting covers July-Sept. I suspect this will be confirmed in Nov...

$ELDN Request for comments on islet bill closes Nov 9th. I believe after midterms this will move back up.

$ELDN What is this price action all of a sudden, 3 consecutive 12-15% days after months of slowly trickling down?

$ELDN $INIS The main catalyst expected to push the price of Radnostix (OTCQB: INIS) is the formal closing of the $13.5 million asset sale to NANO Nuclear Energy (NNE).Here is the timeline and upcoming Press Releases (PR) to watch for:1. NANO Nuclear Deal Closing PR (Expected Late Dec 2026 – Jan 2027)The Setup: On October 1, 2026, INIS announced a definitive agreement to sell its legacy, unbuilt DUF6 and fluorine assets to NANO Nuclear for $9.5 million in cash and $4.0 million in restricted NNE stock. The Progress: On October 19, 2026, the company issued a joint PR confirming they filed a Letter of Intent with the U.S. Nuclear Regulatory Commission (NRC) for the SUB-1011 license transfer.The Driver: Filings state the transaction has a 90 to 120-day closing window from the signing date (Sept 28, 2026). A definitive Press Release confirming the final regulatory approval and receipt of the cash/equity is expected between late December 2026 and January 2027. Receiving $9.5M in cash agains

$ELDN There are a lot of activities after market, I wish I still have dry powder to play it.